Agenus Inc (NAS:AGEN)
$ 3.105 -0.795 (-20.38%) Market Cap: 66.98 Mil Enterprise Value: 71.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Agenus Inc To Host Endpoints Webinar Transcript

Oct 18, 2023 / 05:00PM GMT
Release Date Price: $20.5 (-10.09%)
Surani Fernando

Hi, everyone. I'm Surani Fernando, your moderator for today's Endpoints News webinar. Today -- thanks for joining us for today's session. Sorry, my screen has just done something funny. Thanks for joining us at today's session titled Reactivating the Immune System against Cancer: The Next Immuno-Oncology Revolution.

We're sponsored today by Agenus, and I'm really excited to moderate today's expert panel. Joining us today, we have a great group of panelists. Steven O'Day, Chief Medical Officer at Agenus; Phuong Gallagher, Research Advocate, Training and Support manager at Fight Colorectal Cancer; Pashtoon Kasi, directive for Colorectal Cancer Research at Weill Cornell Medicine; and Benjamin Schlechter, senior physician in gastrointestinal cancer at Dana-Farber Cancer Institute.

Our goals for today's webinar are to share understandings of 3 things: Firstly, what botensilimab or BOT and balstilimab, BAL are showing in clinical trials across multiple tumor types. Secondly, understanding the broader potential of promising new and hopefully, more durable immune activators against

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot